We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ayala Pharmaceuticals Inc (QX) | USOTC:ADXS | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0195 | -3.55% | 0.5305 | 0.5305 | 0.625 | 0.5305 | 0.5305 | 0.5305 | 558 | 14:30:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): September 11, 2017
ADVAXIS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware | 000-28489 | 02-0563870 | ||
(State or Other Jurisdiction | (Commission | (IRS Employer | ||
of Incorporation) | File Number) | Identification No.) |
305 College Road East
Princeton, New Jersey, 08540
(Address of Principal Executive Offices)
(609) 452-9813
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] | Written communications pursuant to Rule 425 under the Securities Act. |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act. |
[ ] | Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act. |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.[ ]
Item 2.02. | Results of Operations and Financial Condition. |
On September 11, 2017, Advaxis, Inc. (“Advaxis” or the “Company”) issued a press release announcing results of operations for the third quarter ended July 31, 2017 and providing a business update. A copy of such press release is being furnished as Exhibit 99.1.
Item 9.01 | Financial Statements And Exhibits. |
(d) | Exhibits. |
99.1 | Press release issued by Advaxis, Inc., dated September 11, 2017. |
- 2 - |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Advaxis, Inc. | ||
(Registrant) | ||
Date: September 11, 2017 | ||
By: | /s/ Sara M. Bonstein | |
Sara M. Bonstein | ||
Executive Vice President and Chief Financial Officer |
- 3 - |
INDEX TO EXHIBITS
Exhibit | ||
Number | Description | |
99.1 | Press release issued by Advaxis, Inc., dated September 11, 2017. |
- 4 - |
1 Year Ayala Pharmaceuticals (QX) Chart |
1 Month Ayala Pharmaceuticals (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions